Testing a new eye drop in healthy adults
Part of Eyes & vision clinical trials.
This trial tests a new eye drop called JMKX003948 in healthy volunteers. It checks if the eye drop is safe and how the body handles it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You are in good general health with no major medical conditions.
- You have no eye problems, previous eye surgery, or serious eye injury.
- Your vision (with glasses or contacts) is 20/20 or better.
- If you are able to have children, you agree to use very effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop or injection called ENN0403 for people with diabetic macular edema (swelling in the back of the eye due to diabetes). The goal is to see if it can improve vision and reduce swelling.
This study tests a new eye drop medicine to see if it is safe and how the body handles it. It is for healthy adults only, not for treating a condition.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
This trial tests whether a new eye drop called BT01001 is safe for healthy adults. You may join if you have good overall and eye health, and do not use contact lenses or have chronic eye problems.
This trial tests whether a new eye drop, JN002, can help people with dry eye disease. It checks if the drops improve symptoms and eye health over time.
This study tests an experimental drug, EXG202, injected into the eye to treat wet age-related macular degeneration (wAMD). It is for people who have already had some benefit from standard treatments in the past 6 months.
Hear when a new Age-Related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.